Fresenius Medical Care AG & Co. KGaA's stock experienced a significant intraday decline of 6.02%.

The plunge follows the company's 2026 financial guidance, which analysts at Jefferies describe as likely to disappoint. The German dialysis specialist forecast broadly flat revenue for the year, with adjusted operating profit expected to range from a mid-single-percentage digit rise to a fall of the same proportion. Despite an anticipated €250 million in savings from an efficiency program, this outlook suggests intensifying headwinds are offsetting these gains.

Furthermore, the company reiterated its 2030 profitability target even after raising its savings goal for 2027, a move that may have contributed to investor concerns about underlying business challenges.